PubMed Health⌕ Search

PubMed · 14721794

Platelet function after off pump coronary surgery.

Abstract

BACKGROUND: Little is known about the impact of off pump coronary artery bypass (OPCAB) on platelet function. Although improved platelet function may decrease bleeding and reduce cerebral and pulmonary damage, there is a concern that changes in platelet function may also accentuate bypass graft occlusion or other thrombotic processes. In this pilot study we used a point-of-care test--Hemostatus (Medtronic, Minneapolis, MN, USA)--to assess changes in platelet function after OPCAB. METHODS: We analyzed data from 11 adult patients undergoing CAB surgery whose platelet function was assessed before and after OPCAB. A Hemostatus test was conducted prior to heparin administration and after protamine reversal. RESULTS: There was a significant improvement in platelet function as measured in both channels 5 and 6 of the Hemostatus test. Blood loss was 598 +/- 244 mL in the first 24 hours. One patient received blood products. CONCLUSION: This pilot study suggests that platelet function is not diminished but instead is improved after OPCAB. This improvement may be due to the release of newer, larger platelets from the bone marrow into the circulation. This finding has important implications for the use of antiplatelet agents perioperatively. Furthermore, more detailed studies in this field are needed.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Benjamin P Bidstrup, Helen Scarrott, Monica Luque. 2003. Platelet function after off pump coronary surgery.. https://pubmed.ncbi.nlm.nih.gov/14721794/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation.

An assay comprising two simple, selective and isocratic HPLC methods with UV detection was developed and validated for measuring warfarin enantiomers and all five warfarin monohydroxylated metabolites in patient blood plasma. Following liquid/liquid extraction from 1 ml of blood plasma a baseline separation of analytes was achieved on chiral (alpha(1) acid glycoprotein - AGP) and achiral (C(18)) column. Both methods were consistent (R.S.D.<6.9% for warfarin enantiomers and<8.9% for monohydroxylated metabolites) and linear (r>0.998). The limits of detection were 25 ng/ml for warfarin enantiomers, 25 ng/ml for 4'-, 10-, 6- and 7-hydroxywarfarin, 35 ng/ml for 8-hydroxywarfarin and 50 ng/ml for racemic warfarin. In a clinical study in 204 patients, it was confirmed that the assay is appropriate for evaluation of influences of genetic polymorphisms, demographic factors and concomitant drug treatment on warfarin metabolism.

Anticoagulants↗

Magnetoelastic transducers for monitoring coagulation, clot inhibition, and fibrinolysis.

Magnetoelastic transduction has been used to detect and monitor the viscosity changes that occur during the biological reactions of coagulation and fibrinolysis. Magnetoelastic sensors can be used, because the characteristic resonance frequency of the magnetoelastic strip shifts in response to the changes in fluid viscosity. At a set frequency, the output signal can be obtained over time to develop a coagulation and/or dissolution profile, which display the change in viscosity of a plasma sample that has undergone either coagulation or fibrinolysis. For coagulation screening, an exogenous tissue factor is added to an anticoagulated plasma sample to initiate coagulation. Further studies were performed to investigate fibrinolysis through the addition of plasmin. Plasmin is used in two different ways-as a competitive inhibitor before the initiation of clotting and also as a protease to dissolve the previously formed clot. This method is a viable option for the monitoring of processes that are paramount to maintaining hemostasis.

Anticoagulants↗